
|Articles|June 1, 2002
Molecule engineered to target neovascularization in AMD
A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Recognizing biomarkers of Alzheimer Disease using OCTA
2
Midyear cataract check-in: What 2026 has brought to the OR and beyond
3
Durability With Aflibercept 8 mg in Retinal Vascular Diseases
4
Next-Generation Anti-VEGF Therapies in Retinal Vascular Diseases
5





















